Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Accumulated Expenses (2017 - 2026)

Catalyst Pharmaceuticals filings provide 11 years of Other Accumulated Expenses readings, the most recent being $745000.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 66.52% to $745000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $745000.0, a 66.52% decrease, with the full-year FY2025 number at $840000.0, up 101.44% from a year prior.
  • Other Accumulated Expenses hit $745000.0 in Q1 2026 for Catalyst Pharmaceuticals, down from $840000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.2 million in Q1 2025 to a low of $372000.0 in Q2 2024.
  • Median Other Accumulated Expenses over the past 4 years was $745000.0 (2026), compared with a mean of $789111.1.
  • Biggest five-year swings in Other Accumulated Expenses: surged 101.44% in 2025 and later tumbled 66.52% in 2026.
  • Catalyst Pharmaceuticals' Other Accumulated Expenses stood at $465000.0 in 2023, then fell by 10.32% to $417000.0 in 2024, then surged by 101.44% to $840000.0 in 2025, then decreased by 11.31% to $745000.0 in 2026.
  • The last three reported values for Other Accumulated Expenses were $745000.0 (Q1 2026), $840000.0 (Q4 2025), and $842000.0 (Q3 2025) per Business Quant data.